Antilipemic Drug -Pharmacology ppt

7,790 views

Published on

Published in: Education, Health & Medicine
1 Comment
9 Likes
Statistics
Notes
No Downloads
Views
Total views
7,790
On SlideShare
0
From Embeds
0
Number of Embeds
10
Actions
Shares
0
Downloads
228
Comments
1
Likes
9
Embeds 0
No embeds

No notes for slide

Antilipemic Drug -Pharmacology ppt

  1. 1. ANTILIPEMIC DRUGS (ANTIHYPERLIPIDEMIC AGENTS) By: MJJH
  2. 2. ANTILIPEMIC DRUGS (ANTIHYPERLIPIDEMIC AGENTS) Used for patients/clients with elevated blood lipids, such as cholesterol, triglycerides, and phospholipids. Drugs are used in combination with lifestyle changes (such as proper diet, weight loss, and exercise) to decrease the risk of CAD.
  3. 3. THE CLASSES OF ANTILIPEMIC DRUGS INCLUDE: BILE-SEQUESTERING DRUGS- The bile- sequestering drugs are cholestyramine, colestipol, and colesevelam. Bile Sequestering drug bind with bile acids, leading to their excretion in the feces.
  4. 4. Pharmacokinetics-Bile-sequestering drugs aren’t absorbed from the GI tract. Instead, they remain in the intestine, where they combine with bile acids for about 5 hours. Eventually, they’re excreted in stool.
  5. 5. Pharmacodynamics-The bile-sequestering drugs lower blood levels of low-density lipoproteins (LDLs). These drugs combine with bile acids in the intestines to form an insoluble compound that’s then excreted in stool. The decreasing level of bile acid in the gallbladder triggers the liver to synthesize more bile acids.
  6. 6. Pharmacotherapeutics- Bile-sequestering drugs are the drugs of choice for treating type ii hyperlipoproteinemia (familial hypercholesterolemia) when the patient can’t lower his LDL levels through diet alone.
  7. 7. Drug interactions- They may bind with acidic drugs in the GI tract, decreasing their absorption and effectiveness. Bile-sequestering drugs may reduce absorption of lipid-soluble vitamins, such as vitamins A, D, E and K. Poor absorption of vitamin K can affect prothrombin times significantly, increasing the risk of bleeding.
  8. 8. ADVERSE REACTIONS TO BILESEQUESTERING DRUGS Short-term adverse reactions to these drugs are relatively mild. More severe reactions can result from long-term use. Adverse GI effects with long-term therapy include severe fecal impaction, vomiting, diarrhea, and hemorrhoid irritation.
  9. 9. FIBRIC ACID DERIVATIVES Fibric acid is produced by several fungi. Two derivatives of this acid are Fenofibrate and gemfibrozil. These drugs are used to reduce high triglyceride levels, and to a lesser extent, high LDL levels.
  10. 10. Pharmacokinetics- Fenofibrate and gemfibrozil are absorbed readily from the GI tract and are highly protein-bound. Fenofibrate is hydrolyzed while gemfibrozil undergoes extensive metabolism in the liver. Both drugs are excreted in the urine.
  11. 11. Pharmacodynamics- Although the exact mechanism of action for these drugs isn’t known, researchers believe that fibric acid derivatives may: •Reduce cholesterol production early in its formation •Mobilize cholesterol from the tissues •Increase cholesterol excretion •Decrease synthesis and secretion of lipoproteins •Decrease synthesis of triglycerides.
  12. 12. Pharmacotherapeutics- Fibric acid drugs are used primarily to reduce triglyceride levels, especially very-low-density triglycerides, and secondarily to reduce blood cholesterol levels. They’re typically used to treat patients with types ii, iii, iv, and mild type v hyperlipoproteinemia.
  13. 13. Drug interactions- Fibric acid drugs may displace acidic drugs, such as barbiturates, phenytoin, thyroid derivatives, and cardiac glycosides. The risk of bleeding increases when fibric acid derivatives are taken with oral anticoagulants.
  14. 14. HMG-COA REDUCTASE (OR 3HYDROXY-3-METHYL-GLUTARYL-COA REDUCTASE OR HMGCR) is the rate-controlling enzyme of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. If these enzyme is blocked, serum cholesterol and LDL levels decrease, because more LDLs are absorbed by the cells for processing into cholesterol. HDL levels increase slightly with this alteration in fat metabolism.
  15. 15. Therapeutic Action and Indications- HMGcoA Reductase inhibitors block the formation of cellular cholesterol, leading to decrease in serum LDLs, with a slight increase or no change in the levels of HDLs. Because these drugs undergo a marked first-pass effect in the liver, most of their effects on the process that generates atheromas in vessel walls. That exact mechanism of action is not understood.
  16. 16. These drugs are indicated as adjuncts with diet and exercise for the treatment of increased cholesterol and LDL levels that are unresponsive to dietary restrictions alone; to slow the progression of CAD in patients with documented CAD; and to prevent first MI in patient who are at risk for MI.
  17. 17. Pharmacokinetics-the statins are all absorbed from the GI tract and undergo the first- pass metabolism in the liver. They are excreted in the feces and urine. The peak effect of this drug is usually seen within 2-4 weeks. These drugs cross the placenta and have been associated with skeletal malformations of he fetus.
  18. 18. Contraindications and action- These drugs are contraindicated in the presence of allergy to any of the statins or to fungal byproducts or compounds. They are also contraindicated with active liver disease or a history of alcoholic liver disease, w/c could exacerbate, leading to severe liver failure.
  19. 19. Adverse Effect- The most common adverse effects associated with these drugs reflect their effects on the GI system: flatulence, abdominal pain, nausea, vomiting, and constipation. CNS effects can include headache, dizziness, blurred vision, fatigue, and cataract development and may effect changes in the cell membrane and synthesis of cholesterol.
  20. 20. Cholesterol Absorption Inhibitors- are a class of compounds that prevents the uptake of cholesterol from the small intestine into the circulatory system. Lower the amount of cholesterol that your body absorbs. So your blood has lower total cholesterol and lower LDL (bad) cholesterol
  21. 21. Therapeutic action and indicationsEzetimibe works in the brush border of the small intestine to decrease the absorption of dietary cholesterol, leading to drop in serum cholesterol levels. It is indicated as an adjunct to diet and exercise to lower cholesterol levels as monotherapy or as part of combination therapy with an HMG-CoA inhibitors or a bile acid sequesterant.
  22. 22. Pharmacokinetics- Ezetimibe is absorbed well after oral administration, reaching peak levels in 4-6 hours. It is metabolized in the liver and the small intestine, with a 22 hours half- life. Excretion in the feces and urine.
  23. 23. Contraindications and CautionsEzetimibe is contraindicated with allergy to any component of the drug. If it is used in combination with a statin, it should not be used during pregnancy or lactation or with severe liver disease because of the known effects of statins, including possible liver problems and renal failure.
  24. 24. Adverse Effect- The most common adverse effect associated with ezetimibe are mild abdominal pain and diarrhea. It is not associated with the bloating and flatulence that occurs with the bile acid sequestrants and fibrates, other adverse effect have been reported include headache, dizziness, fatigue, URI, back pain, muscle aches and pain.
  25. 25. NICOTINIC ACID- Lowers total cholesterol, LDL-cholesterol, and triglyceride levels, while raising HDL-cholesterol levels. Vitamin B (Niacin) or Nicotinic Acid, inhibits release of free fatty acids in the adipose tissue, increases the rate of triglyceride removal form plasma, and generally reduces LDL and triglycerides level and increases HDL levels.
  26. 26. The initial effect on lipid levels is usually seen within 5 to 7 days, with the maximum effect occurring 3 to 5 weeks. Niacin is associated with intense cutaneous flushing, nausea, and abdominal pain, making its use somewhat limited.
  27. 27. It also increases serum levels of uric acid and may predispose patients to the development of gout. Niacin is often combined with bile acid sequestrants fro increased effect. It is given at bedtime to make maximum use of nighttime cholesterol synthesis, and it must be given 4 to 6 hours after bile sequestrant to ensure absorption.

×